Boehringer Ingelheim's bet on Chinese CDMO market pays off with BeiGene's mAb approval

6th January 2020 Uncategorised 0

When China lightened up its rules requiring biologic drug developers to own their own manufacturing, Boehringer Ingelheim took a leap of faith and built a plant there to do contract work under a pilot project. That faith has paid off. 

More: Boehringer Ingelheim's bet on Chinese CDMO market pays off with BeiGene's mAb approval
Source: fierce